Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Accumulated Expenses (2024 - 2025)

Historic Accumulated Expenses for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $9.0 million.

  • Xilio Therapeutics' Accumulated Expenses fell 858.78% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 858.78%. This contributed to the annual value of $10.0 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' Accumulated Expenses is $9.0 million, which was down 858.78% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Accumulated Expenses registered a high of $10.0 million during Q4 2024, and its lowest value of $3.9 million during Q1 2025.